This capstone webinar culminates the ISPOR-IVI series with a reflection on future direction and commitment needed to improve the scientific credibility and relevance of VA/HTA to pandemic preparedness.
COVID-19 has brought home the importance of public health expertise and investment. How should VA/HTA address risks and benefits of public health policy interventions? How do we model the interactions between health and other sectors in our economy? What are the roles of the public vs. private sector in public health infrastructure and interventions? Are there policy implications for public health investment that VA/HTA can help frame?
This webinar features a range of international speakers who will introduce several One Health-related topics as they pertain to HEOR, with a view gauging interest in the formation of an ISPOR Animal and One Health Special Interest Group (SIG).
Evolving data from COVID-19 tell the story we already know: the impact of this disease affects people – especially people of color - disproportionately, both in terms of risk and prevalence, as well as access to care and outcomes. In considering VA/HTA approaches, as well as in discerning how to apply such findings, how must we address questions of ethics and equity?
The methods, assumptions, and inputs to Value Assessment (VA) and Health Technology Assessment (HTA) are an evolving debate in the US, as we seek to balance questions of population health-driven resource allocation with the unique needs of health system, employer, payer, and societal decision-making and the emerging science of patient heterogeneity and precision medicine.
The initial webinar in the series will set the stage with an overview of current issues that the pandemic presents for the assessment of new technologies to prevent, treat, and potentially cure COVID-19, as well as the policy and implementation challenges.
The far-reaching impacts of a pandemic on the US healthcare industry have tremendous implications for pharmaceutical and medical device utilization. Join this session to learn about the short-and long-term effects of a pandemic on healthcare utilization to inform pharmaceutical and medical device companies on how they may need to adjust their analyses of real-world data.
Virtual ISPOR 2020 Preconference Plenary Session - Keynote Address: COVID-19: Accelerating the Evidence to Inform our Response Mark McClellan, MD, PhD, Director, Duke-Margolis Center for Health Policy, Washington, DC, USA Panel: COVID-19: A Global Call to Action for Health Economics & Outcomes Researchers